Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel

**Background:** Docetaxel has been a standard of care for castration-resistant prostate cancer (CRPC) in the United States since 2004, yet little has been reported on its patterns of use in routine practice. To help understand these patterns, a retrospective study was conducted and is reported here....

Full description

Bibliographic Details
Main Authors: Keith L. Davis, Benjamin Gutierrez, Teresa Zyczynski, James A. Kaye
Format: Article
Language:English
Published: Columbia Data Analytics, LLC
Series:Journal of Health Economics and Outcomes Research
Online Access:http://jheor.scholasticahq.com/article/9894-real-world-treatment-patterns-in-men-with-castration-resistant-prostate-cancer-receiving-docetaxel.pdf